Superior predictive value for NTproBNP compared with high sensitivity cTnT in dialysis patients: A pilot prospective observational study

Kidney and Blood Pressure Research

Volumn 39, Issue 6, 2014, Pages 636-647

  Voroneanu, Luminita ^a   Siriopol, Dimitrie ^a   Nistor, Ionut ^a   Apetrii, Mugurel ^a   Hogas, Simona ^a   Onofriescu, Mihai ^a   Covic, Adrian ^a  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Bioimpedance; Biomarkers; Cardiovascular events; Dialysis; Prognosis; Survival

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HIGH SENSITIVITY CARDIAC T TROPONIN; TROPONIN T; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL; AGED; ARTERIAL STIFFNESS; BLOOD; BODY COMPOSITION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY;

AGED; BODY COMPOSITION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL ANALYSIS; TROPONIN T; VASCULAR STIFFNESS;

EID: 84920800056     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368452     Document Type: Article

References (30)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L: United States renal data system 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012;59:A7;e1-420
2. De Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782-1789
3. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF: Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-Analysis. Ann Int Med 2012;157:263-275
4. Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W: Hemoglobin targets for chronic kidney disease patients with anemia: A systematic review and meta-Analysis. PloS one 2012;7:e43655
5. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012;307:674-684
6. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New Engl J Med 2012;367:2482-2494
7. Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, Jin HM: Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: A meta-Analysis of randomised, controlled trials. Br J Nutr 2012;108:400-407
8. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G,Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263
9. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012;23:1087-1096
10. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H Jr, Kopple JD, Greenland S: Revisiting mortality predictability of serum albumin in the dialysis population: Timedependency, longitudinal changes and population-Attributable fraction. Nephrol Dial Transplant 2005;20:1880-1888
11. Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, Yamamoto H, Gallagher M, Port FK, Robinson BM: C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011;6:2452-2461
12. Paniagua R, Ventura MD, Avila-Díaz M, Hinojosa-Heredia H, Méndez-Durán A, Cueto-Manzano A, Cisneros A, Ramos A, Madonia-Juseino C, Belio-Caro F, García-Contreras F, Trinidad-Ramos P, Vázquez R, Ilabaca B, Alcántara G, Amato D: NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant.2010;25:551-557
13. Havekes B, van Manen JG, Krediet RT, Boeschoten EW, Vandenbroucke JP, Dekker FW; NECOSAD Study Group: Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2006;47:823-829
14. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A: Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: A meta-Analysis. Circulation 2005;112:3088-3096
15. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M,Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C: Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-867
16. Smith K, deFilippi C, Isakova T, Gutiérrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M, Christenson R, Wolf M, Januzzi J: Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am J Kidney Dis 2013;61:67-73
17. Kumar N, Michelis MF, DeVita MV, Panagopoulos G, Rosenstock JL: Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay. Nephrol Dial Transplant 2011;26:665-670
18. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Peter A, Thamer C, Weyrich P, Haering HU, Friedrich B: Sensitive troponins-which suits better for hemodialysis patients? Associated factors and prediction of mortality. PLoS One 2012;7:e47610
19. Hassan HC, Howlin K, Jefferys A, Spicer ST, Aravindan AN, Suryanarayanan G, Hall BM, Cleland BD, Wong JK, Suranyi MG, Makris A: High-sensitivity troponin as a predictor of cardiac events and mortality in the stable dialysis population. Clin Chem 2014;60:389-398
20. Wabel P, Moissl U, Chamney P, Jirka T, Machek P, Ponce P, Taborsky P, Tetta C, Velasco N, Vlasak J, Zaluska W, Wizemann V: Towards improved cardiovascular management: The necessity of combining blood pressure and fluid overload. Nephrol Dial Transplant 2008;23:2965-2971
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard H, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463
22. Mongeon FP, Dorais M, Lorier JL, Froment D, Letendre E, Rinfret S: Effect of hemodialysis, coronary artery disease and diabetes on cardiac troponin T: A prospective survey over one year. Open Cardiovasc Med J 2009;3:69-77
23. Kavsak PA, Wang X, Ko DT, MacRae AR, Jaffe AS: Short- and long-term risk stratification using a nextgeneration, high- sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population. Clin Chem 2009;55:1809-1815
24. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE: Over time, high-sensitivity TnT replaces NTproBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta 2010;411:936-939
25. Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, Zeier M: Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007;37:350-356
26. Fernández-Reyes MJ, Mon C, Heras M, Guevara P, Garcia MC, Sanchez R, Velasco S, Alvarez-Ude F: Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. J Nephrol 2004;17:721-727
27. Apple FS, Murakami MM, Pearce LA, Herzog CA: Multi-biomarker risk stratification of N-terminal pro-Btype natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50:2279-2285
28. Satyan S, Light RP, Agarwal R: Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007;50:1009-1019
29. de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A: Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J 2012;163:821-828
30. Hillis GS, Welsh P, Chalmers J, Perkovic V, Chow CK, Li Q, Jun M, Neal B, Zoungas S, Poulter N, Mancia G, Williams B, Sattar N, Woodward M: The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic Peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 2014;37:295-303